Patent: 10,544,125
✉ Email this page to a colleague
Summary for Patent: 10,544,125
Title: | Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts |
Abstract: | The present invention relates a new process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine (AL3818). A stable crystalline form of Al3818 has been prepared. Salts and their crystalline forms of AL3818 have been also prepared. Anti-cancer and optometric activities of AL3818 and its salts have been further tested. New process has been outlined in Scheme I. ##STR00001## |
Inventor(s): | Chen; Guoqing Paul (Westlake, CA), Yan; Changren (Camarillo, CA) |
Assignee: | Advenchen Pharmaceuticals, LLC (Moorpark, CA) |
Application Number: | 16/125,401 |
Patent Claims: | see list of patent claims |
Details for Patent 10,544,125
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bristol-myers Squibb Company | YERVOY | ipilimumab | Injection | 125377 | 03/25/2011 | ⤷ Try a Trial | 2035-05-04 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2035-05-04 |
Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | Injection | 125514 | 01/15/2015 | ⤷ Try a Trial | 2035-05-04 |
Amgen, Inc. | IMLYGIC | talimogene laherparepvec | For Injection | 125518 | 10/27/2015 | ⤷ Try a Trial | 2035-05-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |